LUMOSA THERAPEUTICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 171.5 TWD | -4.19% |
|
-12.72% | +151.10% |
| Sales 2024 * | 65M 2M | Sales 2025 * | 1.57B 48.28M | Capitalization | 28.29B 870M |
|---|---|---|---|---|---|
| Net income 2024 * | -401M -12.33M | Net income 2025 * | 786M 24.17M | EV / Sales 2024 * | 431 x |
| Net cash position 2024 * | 259M 7.97M | Net cash position 2025 * | 954M 29.34M | EV / Sales 2025 * | 17.4 x |
| P/E ratio 2024 * |
-70.6
x | P/E ratio 2025 * |
36
x | Employees | 47 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.19% | ||
| 1 week | -12.72% | ||
| Current month | -3.65% | ||
| 1 month | -5.25% | ||
| 3 months | +36.65% | ||
| 6 months | +187.75% | ||
| Current year | +151.10% |
1 week
163.50
190.50
1 month
163.50233.50
Current year
68.00233.50
1 year
40.65233.50
3 years
30.50233.50
5 years
21.00233.50
10 years
21.00233.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jung Chin Lin
CEO | Chief Executive Officer | 70 | 11-09-15 |
Chia Chi Yang
DFI | Director of Finance/CFO | - | 22-01-31 |
June Kuo
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wan Lai Cheng
BRD | Director/Board Member | - | 14-07-24 |
Jung Chin Lin
CEO | Chief Executive Officer | 70 | 11-09-15 |
I Hsiung Chang
BRD | Director/Board Member | - | 16-01-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 171.5 | -4.19% | 655 161 |
| 24-04-24 | 179 | +6.55% | 543,185 |
| 24-04-23 | 168 | +0.90% | 804,508 |
| 24-04-22 | 166.5 | -8.26% | 2,189,119 |
| 24-04-19 | 181.5 | -4.22% | 1,549,248 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
171.5
TWD
Average target price
2.28
TWD
Spread / Average Target
-98.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +151.10% | 904M | |
| -2.02% | 104B | |
| +1.67% | 97.42B | |
| +0.79% | 22.2B | |
| -17.68% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.01% | 15.06B | |
| +3.70% | 13.98B | |
| +33.51% | 11.66B |
- Stock Market
- Equities
- 6535 Stock
